EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 376 filers reported holding EXELIXIS INC in Q2 2023. The put-call ratio across all filers is 0.08 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $1,079,715 | +186.2% | 45,500 | +189.3% | 0.00% | +100.0% |
Q4 2023 | $377,266 | +59.1% | 15,726 | +45.0% | 0.00% | – |
Q3 2023 | $237,051 | -98.2% | 10,849 | -98.4% | 0.00% | -100.0% |
Q2 2023 | $13,282,768 | -82.2% | 695,069 | -81.9% | 0.03% | -84.5% |
Q1 2023 | $74,452,975 | +1281.0% | 3,835,805 | +1041.3% | 0.19% | +1146.7% |
Q4 2022 | $5,391,124 | -19.2% | 336,105 | -21.0% | 0.02% | -25.0% |
Q3 2022 | $6,672,000 | -42.5% | 425,464 | -16.8% | 0.02% | -45.9% |
Q1 2022 | $11,600,000 | +119.4% | 511,674 | +104.6% | 0.04% | +68.2% |
Q3 2021 | $5,287,000 | -72.4% | 250,076 | -76.2% | 0.02% | -75.6% |
Q2 2021 | $19,128,000 | +24.8% | 1,049,832 | +54.7% | 0.09% | +18.4% |
Q1 2021 | $15,331,000 | +22.0% | 678,671 | +8.4% | 0.08% | +8.6% |
Q4 2020 | $12,570,000 | +74.4% | 626,319 | +49.6% | 0.07% | -17.6% |
Q1 2020 | $7,207,000 | -17.1% | 418,533 | -15.2% | 0.08% | +63.5% |
Q4 2019 | $8,696,000 | +1845.4% | 493,518 | +1853.6% | 0.05% | +1633.3% |
Q3 2019 | $447,000 | +8.8% | 25,262 | +31.5% | 0.00% | 0.0% |
Q2 2019 | $411,000 | -39.7% | 19,215 | -32.9% | 0.00% | -40.0% |
Q1 2019 | $682,000 | +109.2% | 28,636 | +72.9% | 0.01% | +150.0% |
Q4 2018 | $326,000 | -3.3% | 16,562 | -13.0% | 0.00% | 0.0% |
Q3 2018 | $337,000 | -68.9% | 19,032 | -62.2% | 0.00% | -60.0% |
Q2 2018 | $1,082,000 | -92.1% | 50,285 | -91.8% | 0.01% | -91.2% |
Q1 2018 | $13,663,000 | -80.0% | 616,818 | -72.5% | 0.06% | -73.2% |
Q4 2017 | $68,288,000 | +552.6% | 2,246,311 | +420.2% | 0.21% | +419.5% |
Q3 2017 | $10,464,000 | -65.1% | 431,847 | -64.6% | 0.04% | -66.9% |
Q2 2017 | $30,023,000 | +99.6% | 1,218,942 | +75.6% | 0.12% | +77.1% |
Q1 2017 | $15,044,000 | -13.7% | 694,219 | -49.0% | 0.07% | -30.7% |
Q3 2016 | $17,426,000 | +12904.5% | 1,362,500 | +7848.3% | 0.10% | +10000.0% |
Q2 2016 | $134,000 | -68.7% | 17,142 | -84.0% | 0.00% | -66.7% |
Q1 2016 | $428,000 | -23.2% | 106,902 | +8.2% | 0.00% | -25.0% |
Q4 2015 | $557,000 | +322.0% | 98,772 | +320.3% | 0.00% | +300.0% |
Q3 2015 | $132,000 | -90.0% | 23,500 | -93.3% | 0.00% | -87.5% |
Q2 2015 | $1,325,000 | -41.6% | 352,516 | -60.0% | 0.01% | -57.9% |
Q1 2015 | $2,267,000 | -34.6% | 882,135 | -63.3% | 0.02% | -40.6% |
Q4 2014 | $3,465,000 | – | 2,406,399 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |